No. 053 · Combos · Peptide Blend
Sermorelin + Ipamorelin
- Not approved as a combo
- WADA ✗ S2
Combos are blends of separate compounds, so there is no single sequence. This ring motif is decorative — open a component for its fingerprint.
Evidence
- D In vitro
- C Animal
- B Human pilot
- A RCT
- S Approved
Not ranked: combinations have no published studies of their own. See the components below.
A PubMed search found no published studies of this combination; only reviews mention it. Sermorelin was once FDA-approved (Geref, since discontinued); ipamorelin has small human pharmacology studies.
Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.
At a glance
- Routes studied
- Subcutaneous, Intramuscular Routes used in published research
- FDA
- Not approved as a combination
- WADA
- Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
Overview
A well-tolerated GH secretagogue blend pairing the bioidentical GHRH fragment Sermorelin with the selective GHRP Ipamorelin for balanced growth hormone stimulation.
Research status No published studies of the combination; sermorelin was FDA-approved (Geref, since discontinued) and ipamorelin has small human pharmacokinetic studies
Mechanism
This blend combines sermorelin (bioidentical GHRH 1-29 acting via the GHRH receptor/cAMP pathway) with ipamorelin (selective ghrelin receptor agonist acting via IP3/PKC). The dual-pathway synergy amplifies GH pulses while both components maintain selectivity: sermorelin preserves feedback physiology and ipamorelin avoids cortisol/prolactin elevation.
Effects reported in research
These outcomes are attributed to the individual components. The combination itself has not been studied.
- Balanced GH elevation via dual pathways
- Improved sleep quality and recovery
- Enhanced fat metabolism
- Minimal side effects due to selectivity
Safety & unknowns
Both components have established clinical safety histories. Sermorelin was previously FDA-approved (Geref). Ipamorelin has Phase II data. Combined profile expected to be very well-tolerated. Common side effects: headache, flushing, injection site irritation. Not FDA-approved as a combination.
Unknowns. The combination itself has not been studied; interactions between its components are unknown.
Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.
Studies [2]
- Preclinical 1998
Ipamorelin, the first selective growth hormone secretagogue
Rat and swine study on the ipamorelin component showing selective GH release without increases in ACTH or cortisol.
- Clinical trial 1997
Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men
Six-week study of nightly GHRH 1-29 (the sermorelin sequence) in 11 elderly men: some muscle-strength measures improved, with no change in body composition or metabolic measures.
Components
Status sources
Sources behind the tier, regulatory status, sequence and dates on this page.
- Drugs@FDA — NDA 019863 Geref (sermorelin acetate), discontinued accessdata.fda.gov
- Gobburu et al. 1999 — ipamorelin PK/PD in human volunteers pubmed.ncbi.nlm.nih.gov
- WADA 2026 Prohibited List — S2.2.4 names sermorelin and ipamorelin wada-ama.org
Cite this entry
peptidemeta. (2026). Sermorelin + Ipamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/sermorelin-ipamorelin/
@misc{peptidemeta-sermorelin-ipamorelin,
title = {Sermorelin + Ipamorelin},
author = {{peptidemeta}},
year = {2026},
howpublished = {\url{https://peptidemeta.com/p/sermorelin-ipamorelin/}},
note = {Accessed 2026-11-08}
} Accessed date reflects when you opened this page. Cite primary studies for scientific claims.